Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer

Stephanie O. van der Woude; Hanneke W. M. van Laarhoven

doi:https://doi.org/10.1136/bcr-2016-215801

Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer

Stephanie O. van der Woude, Hanneke W. M. van Laarhoven

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway, in combination with paclitaxel is becoming part of standard second-line systemic therapy for advanced oesophagogastric cancer, based on the results of the REGARD and RAINBOW trials. Common well-known side effects of VEGF pathway inhibitors are hypertension and infusion-related reactions. Here, we describe hypertension as the predominant feature of an infusion-related reaction in 2 patients with metastasised oesophagogastric carcinoma treated with ramucirumab and paclitaxel as second-line treatment and propose possible explanations of this side effect previously undescribed for ramucirumab

Original language	English
Journal	BMJ Case Reports
Volume	2016
DOIs	https://doi.org/10.1136/bcr-2016-215801
Publication status	E-pub ahead of print - 2016

Access to Document

https://doi.org/10.1136/bcr-2016-215801

Cite this

@article{2ecd7ecd76804de6aaf087a6b912bbf7,

title = "Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer",

abstract = "Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway, in combination with paclitaxel is becoming part of standard second-line systemic therapy for advanced oesophagogastric cancer, based on the results of the REGARD and RAINBOW trials. Common well-known side effects of VEGF pathway inhibitors are hypertension and infusion-related reactions. Here, we describe hypertension as the predominant feature of an infusion-related reaction in 2 patients with metastasised oesophagogastric carcinoma treated with ramucirumab and paclitaxel as second-line treatment and propose possible explanations of this side effect previously undescribed for ramucirumab",

author = "{van der Woude}, {Stephanie O.} and {van Laarhoven}, {Hanneke W. M.}",

year = "2016",

doi = "https://doi.org/10.1136/bcr-2016-215801",

language = "English",

volume = "2016",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer

AU - van der Woude, Stephanie O.

AU - van Laarhoven, Hanneke W. M.

PY - 2016

Y1 - 2016

N2 - Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway, in combination with paclitaxel is becoming part of standard second-line systemic therapy for advanced oesophagogastric cancer, based on the results of the REGARD and RAINBOW trials. Common well-known side effects of VEGF pathway inhibitors are hypertension and infusion-related reactions. Here, we describe hypertension as the predominant feature of an infusion-related reaction in 2 patients with metastasised oesophagogastric carcinoma treated with ramucirumab and paclitaxel as second-line treatment and propose possible explanations of this side effect previously undescribed for ramucirumab

AB - Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway, in combination with paclitaxel is becoming part of standard second-line systemic therapy for advanced oesophagogastric cancer, based on the results of the REGARD and RAINBOW trials. Common well-known side effects of VEGF pathway inhibitors are hypertension and infusion-related reactions. Here, we describe hypertension as the predominant feature of an infusion-related reaction in 2 patients with metastasised oesophagogastric carcinoma treated with ramucirumab and paclitaxel as second-line treatment and propose possible explanations of this side effect previously undescribed for ramucirumab

U2 - https://doi.org/10.1136/bcr-2016-215801

DO - https://doi.org/10.1136/bcr-2016-215801

M3 - Article

C2 - 27539134

SN - 1757-790X

VL - 2016

JO - BMJ Case Reports

JF - BMJ Case Reports

ER -